BioNexus Gene Lab director granted 32,258 shares

Bin Abdul Hamid Muhammad Azrul reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bin Abdul Hamid Muhammad Azrul reported acquisition or exercise transactions in this Form 4 filing.

BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested stock award of 32,258 Common Shares on August 13, 2026. The award was granted under the company’s 2025 Equity Incentive Plan for completed services, for no cash consideration, and was valued for plan purposes at $1.55 per share, the Nasdaq closing price on August 12, 2026. Following this grant, his direct holdings total 32,258 shares.

Insider Trade Summary

Grant/Award: 32,258 shares

Grant/Award 1 txn

Insider Bin Abdul Hamid Muhammad Azrul

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	32,258	--	--

Holdings After Transaction: Common Shares — 32,258 shares (Direct)

Footnotes (1)

1. F1. Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

Key Figures

Shares granted: 32,258 shares Plan valuation price: $1.55 per share Shares owned after transaction: 32,258 shares

3 metrics

Shares granted 32,258 shares Fully vested Other Stock-Based Award granted on August 13, 2026

Plan valuation price $1.55 per share Nasdaq closing price on August 12, 2026 used for plan valuation

Shares owned after transaction 32,258 shares Total direct holdings of the director following the award

Key Terms

Other Stock-Based Award, no par value, Equity Incentive Plan

3 terms

Other Stock-Based Award financial

"Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock"

no par value financial

"32,258 shares of common stock, no par value, granted on August 13, 2026"

Shares described as "no par value" are equity securities issued without a fixed face amount written into the corporate charter; their legal capital is not tied to a specific per-share number and the company may record proceeds differently than for par-value shares. This matters to investors because it affects how a company records equity, sets minimum legal capital, and handles bookkeeping for issuances, dividends and splits—similar to buying slices of a pie where the slice has no printed sticker price and market forces determine worth.

Equity Incentive Plan financial

"granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioNexus Gene Lab Corp (BGLC) report?

BioNexus Gene Lab Corp reported that director Bin Abdul Hamid Muhammad Azrul received a fully vested award of 32,258 Common Shares on August 13, 2026. The shares were granted for completed services under the 2025 Equity Incentive Plan.

How many BGLC shares did the director acquire in this Form 4 filing?

The director acquired 32,258 Common Shares. These shares were issued as a fully vested Other Stock-Based Award, not purchased on the market, and were granted in recognition of completed services to BioNexus Gene Lab Corp.

At what value was the BGLC stock award to the director measured?

For plan purposes, the 32,258-share award was valued at $1.55 per share, which was the Nasdaq closing price of BioNexus Gene Lab Corp common stock on August 12, 2026, immediately prior to the grant date.

Did the director pay cash for the 32,258 BGLC shares granted?

No, the director paid no cash consideration for the 32,258 shares. The award was granted under the 2025 Equity Incentive Plan as compensation for completed services rather than as a cash purchase of BioNexus Gene Lab Corp stock.

What are the director’s BGLC holdings after this stock award?

After the August 13, 2026 award, the director directly holds 32,258 Common Shares of BioNexus Gene Lab Corp. The Form 4 reports this number as his total direct ownership following the transaction.

Under which plan was the BGLC stock granted to the director?

The shares were granted under the BioNexus Gene Lab Corp 2025 Equity Incentive Plan. The Form 4 describes the grant as a fully vested Other Stock-Based Award of 32,258 shares for completed services, with no cash consideration paid.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:19 PM Accepted by SEC EDGAR 08/14/2026 - 05:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bin Abdul Hamid Muhammad Azrul

(Last) (First) (Middle)

NO 16 LORONG TABAN 2

LUCKY GARDEN BANGSAR

(Street)

BANGSAR KUALA LUMPUR 59100

(City) (State) (Zip)

MALAYSIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioNexus Gene Lab Corp [ BGLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/13/2026		A		32,258	A	(1)	32,258	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

	/s/ Muhammad Azrul Bin Abdul Hamid	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)